1. Home
  2. PLBY vs BNR Comparison

PLBY vs BNR Comparison

Compare PLBY & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBY

PLBY Group Inc.

HOLD

Current Price

$1.30

Market Cap

204.4M

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$9.21

Market Cap

179.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBY
BNR
Founded
1953
2014
Country
United States
China
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
204.4M
179.7M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
PLBY
BNR
Price
$1.30
$9.21
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
1.1M
14.5K
Earning Date
05-11-2026
06-05-2026
Dividend Yield
N/A
N/A
EPS Growth
87.50
N/A
EPS
N/A
N/A
Revenue
$120,928,000.00
N/A
Revenue This Year
$9.17
$111.65
Revenue Next Year
$7.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.13
N/A
52 Week Low
$1.19
$2.95
52 Week High
$2.75
$41.72

Technical Indicators

Market Signals
Indicator
PLBY
BNR
Relative Strength Index (RSI) 37.11 26.83
Support Level $1.22 $7.99
Resistance Level $1.94 $9.70
Average True Range (ATR) 0.08 1.19
MACD 0.01 -0.50
Stochastic Oscillator 33.90 6.87

Price Performance

Historical Comparison
PLBY
BNR

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

Share on Social Networks: